Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 6:14 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2329–2352 of 2,455 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: ABI-007(Abraxane) Clear all

Conditions: Breast Cancer
Interventions: Pertuzumab, Trastuzumab, Aromatase Inhibitor, Induction Chemotherapy; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 21
States / cities: Birmingham, Alabama • Chandler, Arizona • Hot Springs, Arkansas + 17 more

Conditions: Primary Peritoneal Carcinoma, Stage III Ovarian Cancer, Stage IV Ovarian Cancer
Interventions: Paclitaxel, Carboplatin, Gemcitabine Hydrochloride, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan Hydrochloride, Therapeutic Conventional Surgery; Drug · Procedure
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: Female only
Enrollment: 4,312 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2013
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Anaplastic Thyroid Cancer, Recurrent Thyroid Cancer
Interventions: efatutazone, paclitaxel; Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 253
States / cities: Anchorage, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 168 more

Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size, Extraocular Extension Melanoma, Iris Melanoma, Metastatic Intraocular Melanoma, Recurrent Intraocular Melanoma
Interventions: carboplatin, paclitaxel, sorafenib tosylate; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Breast Cancer
Interventions: Paclitaxel, microarray analysis, biopsy, neoadjuvant therapy; Drug · Genetic · Procedure
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2012
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Prostate Cancer
Interventions: bicalutamide, estramustine phosphate sodium, etoposide, flutamide, paclitaxel, Luteinizing hormone releasing hormone [LHRH] agonist, Radiation therapy, warfarin; Drug · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older · Male only
Enrollment: 397 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2013
U.S. locations: 52
States / cities: Birmingham, Alabama • Phoenix, Arizona • Concord, California + 43 more

Conditions: Endometrial Cancer, Recurrent or Progressive Endometrial Cancer
Interventions: Rina-S, IC; Drug
Lead sponsor: Genmab; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 660 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 69
States / cities: Mobile, Alabama • Phoenix, Arizona • Irvine, California + 51 more

Conditions: Breast Cancer, Male Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions: tipifarnib, paclitaxel, doxorubicin, cyclophosphamide; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 7
States / cities: Tampa, Florida • New York, New York • The Bronx, New York + 1 more

Conditions: Neoplasms, Breast
Interventions: GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2302024A, Placebo, Aromatase inhibitor, 5-Fluorouracil, Carboplatin AUC, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin, Paclitaxel, Trastuzumab; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 8
States / cities: Newark, Delaware • Plantation, Florida • Boston, Massachusetts + 5 more

Conditions: Melanoma
Interventions: LOC-paclitaxel; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Platinum-resistant Ovarian Cancer
Interventions: Paclitaxel, Afuresertib; Drug
Lead sponsor: Laekna Limited; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 30
States / cities: Phoenix, Arizona • Tucson, Arizona • Rogers, Arkansas + 25 more

Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
Interventions: Atezolizumab, Capecitabine, Carboplatin, Ipatasertib, Paclitaxel, Quality-of-Life Assessment, Questionnaire Administration; Drug · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Duarte, California

Conditions: Head and Neck Cancer
Interventions: cetuximab, cisplatin, fluorouracil, paclitaxel; Biological · Drug
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 3
States / cities: Camden, New Jersey • Lakewood, New Jersey • Long Branch, New Jersey

Conditions: Lung Cancer
Interventions: paclitaxel; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Ovarian Cancer
Interventions: Oral Ascorbic Acid, Paclitaxel, Carboplatin, Sodium Ascorbate, Oral Mixed natural Carotenoids with Vitamin A, Vitamin E; Dietary Supplement · Drug
Lead sponsor: Jeanne Drisko, MD, CNS, FACN; Other
Eligibility: 18 Years and older · Female only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Oropharyngeal Squamous Cell Carcinoma
Interventions: Transoral Robotic Surgery (TORS) or Radiotherapy, Chemotherapy and Low-Dose Radiotherapy, Chemotherapy and High-Dose Radiotherapy, Paclitaxel, Carboplatin; Other · Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Non-Squamous Non-Small Cell Lung Cancer
Interventions: GDC-0941, bevacizumab, carboplatin, cisplatin, paclitaxel, pemetrexed; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Lymphoma
Interventions: filgrastim, monoclonal antibody Lym-1, cyclosporine, paclitaxel, peripheral blood stem cell transplantation, indium In 111 monoclonal antibody Lym-1, yttrium Y 90 monoclonal antibody Lym-1; Biological · Drug · Procedure + 1 more
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Breast Cancer, Peripheral Neuropathy
Interventions: Desloratodine, Placebo; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Esophageal, Toxicity
Interventions: Manganese Superoxide Dismutase Plasmid Liposome, carboplatin, paclitaxel, Radiation Therapy; Genetic · Drug · Radiation
Lead sponsor: Joel Greenberger; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Advanced Solid Neoplasm
Interventions: Pevonedistat, Rifampin, Docetaxel, Carboplatin, Paclitaxel; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 4
States / cities: Atlanta, Georgia • Chicago, Illinois • Detroit, Michigan + 1 more

Conditions: Lung Cancer
Interventions: carboplatin, cisplatin, efaproxiral, gemcitabine hydrochloride, paclitaxel, vinorelbine ditartrate, radiation therapy; Drug · Procedure
Lead sponsor: Spectrum Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 8
States / cities: Phoenix, Arizona • Coeur d'Alene, Idaho • Lexington, Kentucky + 4 more

Conditions: Pancreas Cancer
Interventions: Gemcitabine, Nab paclitaxel, IM156; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Non-Small Cell Lung Cancer
Interventions: MK-3475, Carboplatin, Paclitaxel, Pemetrexed; Drug
Lead sponsor: Alliance Foundation Trials, LLC.; Other
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 11
States / cities: La Jolla, California • Chicago, Illinois • Evanston, Illinois + 8 more

Search by objective public record fields.

A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer

Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer

Sorafenib, Carboplatin, and Paclitaxel in Treating Patients With Stage IV Melanoma of the Eye

Genetic Testing in Predicting Response to Paclitaxel in Women With Breast Cancer

Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer

Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer

Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer

Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer

Study of Weekly LOC-paclitaxel Injection for Melanoma

Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian

Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer

Cetuximab Plus Cisplatin in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck That Has Not Responded to Cisplatin Chemotherapy

Paclitaxel in Treating Patients With Recurrent or Refractory Non-small Cell Lung Cancer

Treatment of Newly Diagnosed Ovarian Cancer With Antioxidants

Pilot Study of Chemotherapy for HPV-Associated Oropharyngeal Cancer

A Study of the Safety and Pharmacology Of PI3-Kinase Inhibitor GDC-0941 In Combination With Either Paclitaxel And Carboplatin (With or Without Bevacizumab) or Pemetrexed, Cisplatin, And Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer

Monoclonal Antibody Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Refractory Non-Hodgkin's Lymphoma

Desloratadine to Prevent Taxane-induced Peripheral Neuropathy in Patients With Breast Cancer

MnSOD (Esophageal Protectant) to Prevent Esophagitis During Radiation/Chemotherapy Treatment for Non-Small Cell Lung Cancer (NSCLC)

A Study to Evaluate the Effects of Rifampin on Pharmacokinetics (PK) of Pevonedistat in Participants With Advanced Solid Tumors

Chemotherapy and Radiation Therapy With or Without Efaproxiral in Treating Patients With Stage III Non-Small Cell Lung Cancer

A Phase 1b Study of Gemcitabine and Nab-paclitaxel in Combination With IM156 in Patients With Advanced Pancreatic Cancer.

Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLC